<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00786123</url>
  </required_header>
  <id_info>
    <org_study_id>D/06/136</org_study_id>
    <nct_id>NCT00786123</nct_id>
  </id_info>
  <brief_title>Exploring the Mechanism of a Probiotic Combination VSL#3 in Irritable Bowel Syndrome</brief_title>
  <official_title>Exploring the Mechanism of a Probiotic Combination VSL#3 in Irritable Bowel Syndrome: a Randomized Double Blind Placebo Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National University Hospital, Singapore</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National University Hospital, Singapore</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Irritable bowel syndrome (IBS) is a very common chronic gastrointestinal disorder. Existing&#xD;
      therapies for IBS are still far from satisfactory and new therapies are being constantly&#xD;
      sought. Probiotics are promising candidate for the prevention and treatment of IBS. However,&#xD;
      its efficacy and mechanism is still unclear. The current study aims to evaluate the effects&#xD;
      of a combination probiotic, VSL#3, on symptoms and rectal sensitivity in patients with IBS.&#xD;
      The underlying mechanism will also be investigated. We will recruit forty patients with Rome&#xD;
      III IBS and randomized them, in a parallel group, double-blinded design, to take four VSL#3&#xD;
      capsules or placebos, twice daily, for six weeks. Before and after treatment, patients will&#xD;
      be assessed for their symptoms, rectal sensitivity, as well as saliva and fecal melatonin&#xD;
      levels. Bowel symptom diary and weekly satisfactory relief of bowel symptoms will also be&#xD;
      recorded and evaluated.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2006</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Resolution of symptoms</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rectal sensitivity</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Saliva and fecal melatonin levels</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Irritable Bowel Syndrome</condition>
  <arm_group>
    <arm_group_label>VSL#3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients taking probiotics (VSL#3)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Identical looking preparation of placebo taken at the same dose regimen as the active comparator</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>VSL#3</intervention_name>
    <description>Dose: 4 capsules of VSL#3 daily for 6 weeks.</description>
    <arm_group_label>VSL#3</arm_group_label>
    <other_name>probiotics</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Identical looking preparation of placebo taken at the same dose regimen as the active comparator</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female and male patients with IBS between the ages of 18 and 68 will be recruited. IBS&#xD;
             will be diagnosed according to the Rome III diagnostic criteria (Drossman and&#xD;
             Dumitrascu, 2006). The history of previous chronic GI symptoms suggestive of IBS&#xD;
             should be at least 3 months (not necessarily consecutive) over the preceding 6 months.&#xD;
             The stool culture of each subject should be negative for hemoccult, pathogens&#xD;
             (Salmonella and Shigella), parasites (Giardia) and ova/ cyst. Only patients who had&#xD;
             IBS symptoms for at least one month prior to the study and whose IBS symptom score is&#xD;
             of at least a moderate severity on at least one of IBS symptoms will be eligible for&#xD;
             inclusion into the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Those subjects who are unwilling or unable to give informed consent, follow protocol&#xD;
             or to stop all medications used to treat diarrhoea or colitis&#xD;
&#xD;
          -  Subject taking at the time of proposed enrolment any of the below listed prohibited&#xD;
             medications:&#xD;
&#xD;
               -  Anticholinergics (dicyclomine, hyoscyamine, propantheline)&#xD;
&#xD;
               -  Cholinomimetic agents (bethanechol etc.)&#xD;
&#xD;
               -  All narcotics (morphine, codeine, propoxyphene either alone or in any&#xD;
&#xD;
               -  combination)&#xD;
&#xD;
               -  5-HT3 receptor antagonists (e.g., alosetron, ondansetron, tropisetron,&#xD;
                  dolasetron, granisetron).&#xD;
&#xD;
               -  Gastrointestinal preparations:&#xD;
&#xD;
               -  Antacids (containing either magnesium or aluminium)&#xD;
&#xD;
               -  Antidiarrheal agents&#xD;
&#xD;
               -  Bismuth compounds&#xD;
&#xD;
               -  Laxatives (stimulant or osmotic)&#xD;
&#xD;
               -  Sulfasalazine&#xD;
&#xD;
          -  Treatment with immunosuppressive medications or presence of an immunocompromised state&#xD;
&#xD;
          -  If currently using medication (like those used in Diabetes mellitus, Sarcoidosis,&#xD;
             Connective tissue disease, poorly controlled hypo/hyperthyroidism) may alter bowel&#xD;
             motility or if under long term antibiotic therapy&#xD;
&#xD;
          -  Use of any other investigational drug and/or participation in any clinical trial&#xD;
             within 3 months of entry to this study&#xD;
&#xD;
          -  Patients will be excluded if they had undergone previous abdominal surgery (except&#xD;
             appendectomy, Caesarean section, Cholecystectomy, Tubal ligation, Hysterectomy, Hernia&#xD;
             repair â‰¥ 6 months prior to enrolment)&#xD;
&#xD;
          -  Subject who has been diagnosed with any of the following GI disorders:&#xD;
&#xD;
               -  Inflammatory bowel disease (Crohn's disease, Ulcerative colitis, Indeterminate&#xD;
                  Colitis&#xD;
&#xD;
               -  Microscopic colitis (lymphocytic colitis, collagenous colitis)&#xD;
&#xD;
               -  Celiac Disease&#xD;
&#xD;
               -  Gastroparesis&#xD;
&#xD;
               -  Gastrointestinal obstruction and/or stricture&#xD;
&#xD;
               -  Chronic pancreatitis&#xD;
&#xD;
          -  Subject with a significant concomitant psychiatric, neurological, metabolic, renal,&#xD;
             hepatic, infections, hematological, C.V or pulmonary illness, unless condition is&#xD;
             stable and judged by the investigator that such condition does not interfere with the&#xD;
             patients participation in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>68 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ho Khek Yu</last_name>
    <role>Principal Investigator</role>
    <affiliation>National University Hospital, Singapore</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National University Hospital</name>
      <address>
        <city>Singapore</city>
        <zip>119074</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Singapore</country>
  </location_countries>
  <reference>
    <citation>Camilleri M. Is there a role for probiotics in irritable bowel syndrome? Dig Liver Dis. 2006 Dec;38 Suppl 2:S266-9. Review.</citation>
    <PMID>17259088</PMID>
  </reference>
  <reference>
    <citation>Shen B, Brzezinski A, Fazio VW, Remzi FH, Achkar JP, Bennett AE, Sherman K, Lashner BA. Maintenance therapy with a probiotic in antibiotic-dependent pouchitis: experience in clinical practice. Aliment Pharmacol Ther. 2005 Oct 15;22(8):721-8.</citation>
    <PMID>16197493</PMID>
  </reference>
  <reference>
    <citation>Song GH, Venkatraman V, Ho KY, Chee MW, Yeoh KG, Wilder-Smith CH. Cortical effects of anticipation and endogenous modulation of visceral pain assessed by functional brain MRI in irritable bowel syndrome patients and healthy controls. Pain. 2006 Dec 15;126(1-3):79-90. Epub 2006 Jul 18.</citation>
    <PMID>16846694</PMID>
  </reference>
  <reference>
    <citation>Song GH, Leng PH, Gwee KA, Moochhala SM, Ho KY. Melatonin improves abdominal pain in irritable bowel syndrome patients who have sleep disturbances: a randomised, double blind, placebo controlled study. Gut. 2005 Oct;54(10):1402-7. Epub 2005 May 24.</citation>
    <PMID>15914575</PMID>
  </reference>
  <verification_date>March 2011</verification_date>
  <study_first_submitted>November 4, 2008</study_first_submitted>
  <study_first_submitted_qc>November 4, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 6, 2008</study_first_posted>
  <last_update_submitted>March 2, 2011</last_update_submitted>
  <last_update_submitted_qc>March 2, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 4, 2011</last_update_posted>
  <responsible_party>
    <name_title>Khek Yu Ho / Professor</name_title>
    <organization>National University Hospital, Singapore</organization>
  </responsible_party>
  <keyword>irritable bowel syndrome</keyword>
  <keyword>rectal hypersensitivity</keyword>
  <keyword>probiotics</keyword>
  <keyword>melatonin</keyword>
  <keyword>brain-gut axis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irritable Bowel Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>November 6, 2012</submitted>
    <returned>December 4, 2012</returned>
    <submitted>June 20, 2013</submitted>
    <returned>July 26, 2013</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

